FDA Commissioner Delivers Remarks at FDA-U.S. Patent and Trademark Office Public Workshop
Amgen Releases 2022 Biosimilar Trends Report
Recent and Proposed Legislation Affecting Biosimilars
Biocon and Alvotech Release Statements on FDA Inspections
FDA Accepts for Review Fresenius Kabi’s BLA for Tocilizumab Biosimilar
Formycon Q1 2022 Financial Results and Announcement of Two New Biosimilar Products
EMA Recommends Denying Marketing Authorization for Prestige BioPharma’s TUZNUE and HERVELOUS (trastuzumab)
FDA Approves Amneal’s ALYMSYS (bevacizumab-maly)
JAMA Oncology Publishes Results of Phase III Study for Prestige BioPharma’s HERCEPTIN Biosimilar, HD201
Subscribe: Subscribe via RSS
Blogs
Firm/Org